In May, we added 105 citations in DIDB, including 48 in vitro (with 27 articles published in April 2024) and 57 in vivo articles (with 37 articles published in April 2024).
6 NDA/BLAs approved in 2024, including aprocitentan (TRYVIO), nogapendekin alfa inbakicept (ANKTIVA), pegulicianine (LUMISIGHT), sotatercept (WINREVAIR), tovorafenib (OJEMDA), and vadadustat (VAFSEO), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.